Discovery on Target 2026 has ended. This guide stays up as the record of who was there. Next: Discovery on Target 2027, Oct 18–21, 2027 in Boston

Lead generation strategies at Discovery on Target 2026

Sep 28 – Oct 1, 2026 Boston, MA ~1.1k attendees Website

54 organizations at Discovery on Target 2026 present work in lead generation strategies: 29 technology and service providers, 14 drug developers and 11 academic, government and non-profit bodies. Between them they bring 89 presentations to the program. Most represented: Pfizer, Genentech and University of California, San Francisco. As of Oct 8, 2026.

All 510 organizations at Discovery on Target 2026 →

Showing 1–7 of 54 organizations

Organization	Discovery on Target 2026 Attendance
Pfizer New York, NY
pfizer.com Large pharma Global pharmaceutical company developing medicines and vaccines in oncology, inflammation and immunology, internal medicine and rare diseases.	Chair Tue Sep 29 1:45pm–1:50pm Chairperson's Remarks Emerging Drug Targets Talk Tue Sep 29 2:20pm–2:50pm Discovery of Potent and Brain-Penetrant Inverse Agonists for GPR61, an Orphan GPCR Emerging Drug Targets Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Panel Wed Sep 30 7:30am–8:15am Modern GPCR-Targeted Drug Discovery Lead Generation Strategies · with Computational Therapeutics Discovery Talk Wed Sep 30 11:50am–12:20pm A GIPR Small-Molecule Antagonist for Obesity Lead Generation Strategies Chair Wed Sep 30 2:00pm–2:05pm Chairperson's Remarks Lead Generation Strategies Talk Wed Sep 30 2:35pm–3:05pm Fragment Screening and Hit Optimization for an Orphan GPCR Using 19F-NMR and SPR Techniques Lead Generation Strategies Panel Thu Oct 1 7:30am–8:15am Building the Next Generation of DEL Datasets for AI Lead Generation Strategies Talk Thu Oct 1 9:35am–10:05am Extracting Actionable SAR from Primary DEL Screens to Drive Early Lead Optimization Lead Generation Strategies Talk Thu Oct 1 3:30pm–4:00pm Antibody-Drug Conjugate Immunogenicity: Current Landscape and Strategies to De-Risk Development Next-Generation Conjugates
Genentech South San Francisco, CA
gene.com Large pharma Biotechnology company and member of the Roche Group, discovering and developing medicines in oncology, immunology and neuroscience.	Talk Mon Sep 28 10:15am–10:45am AI-empowered Early Target Discovery with MARS: Multimodal Platform for Target Prioritization and Modality Selection Symposium: Generative AI/Machine Learning-Driven Drug Design Talk Tue Sep 29 11:05am–11:35am Molecular Basis of CXC Chemokine Receptor 3 Ligand Multispecificity Antibodies Against Challenging Targets Talk Wed Sep 30 12:20pm–12:50pm Template-Driven Scaffolding of SCFFBXO42 Regulates PP2A Degradation Emerging Drug Targets Talk Wed Sep 30 2:05pm–2:35pm Accelerating T Cell Engager Immunotherapy Discovery with High-Throughput Kinetic Multiparametric Platform Antibodies Against Challenging Targets Talk Thu Oct 1 11:50am–12:20pm Discovery of Novel Activators for Lysosome Ion Channel TMEM175, a Parkinson's-Disease Target Emerging Drug Targets Talk Thu Oct 1 4:05pm–4:35pm Using Metal Ions to Identify Novel PPI Binding Sites Lead Generation Strategies Talk Thu Oct 1 4:35pm–5:05pm Mechanistic Insights into Hit-Selection Based on DEL Screening Lead Generation Strategies
University of California, San Francisco San Francisco, CA
	Panel Mon Sep 28 5:00pm–6:00pm Where and How Can Open Source AI/ML Learning Impact Drug Development? Symposium: Generative AI/Machine Learning-Driven Drug Design · with PsiThera, Ginkgo Bioworks, Eli Lilly +3 more Talk Tue Sep 29 10:35am–11:35am Ninhydrin as a Covalent Warhead-Targeting Arginine Lead Generation Strategies Talk Tue Sep 29 11:35am–12:05pm Snapshots of the Cell Surface: Mapping Protein Neighborhoods Using Contact-dependent Antibody Mapping (contactMAP) Antibodies Against Challenging Targets Talk Wed Sep 30 11:50am–12:20pm Targeted Degradation of Extracellular Proteins via Induced Shedding Novel Drug Modalities Talk Wed Sep 30 12:20pm–12:50pm Making "n=1" Therapies Accessible for All with Computational Target Prediction Innovative Discovery Technologies Talk Thu Oct 1 10:05am–10:35am Structure-Guided Engineering of a Conformation-Specific Antibody–Drug Conjugate for AML Antibodies Against Challenging Targets Talk Thu Oct 1 10:35am–11:05am Chemical Strategies to Expand the Therapeutic Window for Targeted Radiotherapy Radioligand Therapies
Novartis Basel, Switzerland
novartis.com Large pharma Global pharmaceutical company; Novartis Biomedical Research is its drug discovery arm.	Panel Mon Sep 28 10:45am–11:30am Implementation of Computational Strategies for Driving Proximity-Induced Therapies Symposium: Induced Proximity-Based Drug Discovery · with Barcelona Supercomputing Center, InduPro, Foghorn Therapeutics Talk Tue Sep 29 2:20pm–2:50pm From PSMA to What’s Next: Evolving the Radioligand Target Landscape Radioligand Therapies Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Talk Wed Sep 30 2:05pm–2:35pm Exploring the Impact of Ligand and Payload Design on ADC Therapeutic Index Using Quantitative Systems Pharmacology and Physiologically Based Pharmacokinetic Modeling Next-Generation Conjugates Panel Thu Oct 1 7:30am–8:15am Direct-to-Biology (D2B) Lead Generation Strategies
Bristol Myers Squibb Princeton, NJ
bms.com Large pharma Global biopharmaceutical company with medicines in oncology, immunology, cardiovascular disease and neuroscience.	Talk Tue Sep 29 8:35am–9:05am Advancing KRAS G12C Active-State Inhibition through Next-Generation Covalent Warhead Design Lead Generation Strategies Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Amgen, Novartis +3 more Novel drug modalitiesInnovative discovery technologies Panel Wed Sep 30 7:30am–8:15am Covalent Drug Design Strategies Lead Generation Strategies · with GSK Talk Thu Oct 1 12:20pm–12:50pm Direct-to-Biology Discovery of BMS-986526, an EP4 Agonist for the Treatment of Inflammatory Bowel Disease Lead Generation Strategies Talk Thu Oct 1 3:35pm–4:05pm Discovery of BMS-986196: A Brain-Penetrant, Covalent Inhibitor of Bruton’s Tyrosine Kinase (BTK) Emerging Drug Targets
GSK London, UK
gsk.com Large pharma Global biopharmaceutical company developing vaccines and medicines in infectious disease, HIV, respiratory, immunology and oncology.	Talk Tue Sep 29 11:35am–12:05pm Covalent Methods in DNA-Encoded Library (DEL) Drug Discovery Lead Generation Strategies Panel Wed Sep 30 7:30am–8:15am Covalent Drug Design Strategies Lead Generation Strategies · with Bristol Myers Squibb Chair Thu Oct 1 9:00am–9:05am Chairperson's Remarks Lead Generation Strategies Talk Thu Oct 1 9:05am–9:35am DEL Applications to Protein-Degrader Discovery Lead Generation Strategies
Revolution Medicines Redwood City, CA
revmed.com Biotech Oncology company developing oral RAS(ON) inhibitors for RAS-driven cancers.	Talk Tue Sep 29 9:05am–9:35am Zoldonrasib, an Oral, RAS(ON) G12D-Selective, Covalent, Tri-Complex Inhibitor Lead Generation Strategies Talk Tue Sep 29 9:35am–10:05am Discovery of Diverse RAS(ON) Inhibitor Profiles by Chemically Remodeling a Cellular Chaperone Novel Drug Modalities Panel Wed Sep 30 5:50pm–6:30pm Connect the DOTS for Start-Ups & Funding Plenary · with Nova Rain Capital, Ilerabio Panel Thu Oct 1 7:30am–8:15am Setting Up Collaborations & Partnerships Plenary · with Johnson & Johnson